Anagliptin vs Evogliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Anagliptin · Suiny

Marketed by Sanwa Kagaku Kenkyusho and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT01529541 · Phase 3 · completed

The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.

Next expected readout: March 2027 · NCT07442006 (registry estimate)

Reported efficacy

The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)

Result source: NCT01529528

Evogliptin · Suganon

Marketed by Dong-A ST and partners

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT02949193 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial (n=222) comparing evogliptin against sitagliptin, both added to metformin. The prespecified non-inferiority comparison for the primary endpoint, HbA1c change at 24 weeks, was met: the between-group difference and its confidence interval stayed within the non-inferiority range.

Reported efficacy

Change from baseline in HbA1c (%) After 24 weeks: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001) (met)

Result source: NCT04170998

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnagliptinEvogliptin
HbA1c, change-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
-0.2% vs 0.1%a−0.3 vs placeboevogliptin 5mg · wk 24NCT02946541
2 other results
  • -0.6% vs -0.0% wk 52 · Phase 3 · primary NCT04170998
  • -0.6% vs -0.7% evogliptin 5mg · wk 24 · Phase 3 · primary NCT02949193
Body weight, change (kg)—Not posted · NCT01529528—Not posted · NCT02949193
HbA1c below 7%—Not posted · NCT01529528—Not posted · NCT02949193
Fasting plasma glucose, change—Not posted · NCT01529528—Not posted · NCT02949193
3-point MACE (% with event)—Not posted · NCT01529528—Not posted · NCT02949193

HbA1c, change

Anagliptin
-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
Evogliptin
-0.2% vs 0.1%a−0.3 vs placeboevogliptin 5mg · wk 24NCT02946541
2 other results
  • -0.6% vs -0.0% wk 52 · Phase 3 · primary NCT04170998
  • -0.6% vs -0.7% evogliptin 5mg · wk 24 · Phase 3 · primary NCT02949193

Body weight, change (kg)

Anagliptin
—Not posted · NCT01529528
Evogliptin
—Not posted · NCT02949193

HbA1c below 7%

Anagliptin
—Not posted · NCT01529528
Evogliptin
—Not posted · NCT02949193

Fasting plasma glucose, change

Anagliptin
—Not posted · NCT01529528
Evogliptin
—Not posted · NCT02949193

3-point MACE (% with event)

Anagliptin
—Not posted · NCT01529528
Evogliptin
—Not posted · NCT02949193
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Evogliptin

HbA1c -0.65% @ 24wk
absolute change · percentage points
No placebo or comparator arm
NCT04170998 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Evogliptin's landscape